A three-stage design for allergen immunotherapy trials.

Area of Science:

• Allergy and Immunology
• Clinical Trial Design
• Biostatistics

Background:

• Allergen immunotherapy (AIT) clinical trials are lengthy, often exceeding 5 years.
• High dropout rates, particularly in placebo groups, complicate trial interpretation.
• A proposed three-stage design aims to mitigate these challenges.

Purpose of the Study:

• To introduce and validate a three-stage clinical trial design for AIT.
• To assess clinical efficacy, treatment response over time, and sustained post-treatment benefits.
• To provide a statistical framework for evaluating AIT using inferential statistics.

Main Methods:

• A three-stage design with placebo crossover to active treatment in Stage 2.
• Stage 3 involves treatment discontinuation to assess sustained response.
• Inferential statistics and simulation studies were used to evaluate design properties.

Main Results:

• The design's statistical properties (bias, power) align with conventional analyses.
• Bias is influenced by missing data mechanisms and effect size.
• With 25% relative difference and 15% dropout, 200 participants/group yield 93% power for treatment effect and 60% for sustained response.

Conclusions:

• Inferential statistics support the proposed three-stage design for AIT trials.
• The design enhances the evaluation of AIT benefits over time.
• This framework can inform clinical understanding and decision-making in AIT research.